血液肿瘤检测市场、机会、成长动力、产业趋势分析与预测，2024-2032

2023 年，全球血液肿瘤检测市场估值为32 亿美元，预计2024 年至2032 年复合年增长率为14.2%。率不断上升推动的，导致对先进诊断测试的需求增加。诊断技术的进步，加上人们对血液癌症的认识提高以及早期检测的好处，正在显着推动市场发展。对早期筛检的日益关注和更专业的检测解决方案的开发继续推动市场向前发展。

血液肿瘤学检测致力于血液相关癌症的检测、诊断和监测。这些测试可识别基因突变、染色体异常以及与血液恶性肿瘤相关的其他生物标记物，从而增强更有效地管理这些疾病的能力。

整个血液肿瘤检测产业根据产品和服务、癌症类型、技术、最终用途和地区进行分类。

市场分为试剂盒和试剂、仪器以及软体和服务。仪器部分包括次世代定序（NGS）、聚合酶链反应（PCR）、流式细胞仪、细胞遗传学和免疫组织化学。 2023 年，在个人化医疗需求不断增长和诊断测试进步的推动下，试剂盒和试剂领域占据主导地位，收入达 17 亿美元。血液学诊断的持续研究和开发进一步刺激了市场扩张，FDA 和 EMA 等机构的监管批准支持了成长。

市场分为白血病、淋巴瘤和其他癌症。由于霍奇金淋巴瘤和非何杰金氏淋巴瘤的发生率不断上升，淋巴瘤在 2023 年占据了 51.3% 的领先市场。改进的筛检计划和诊断技术有助于该细分市场的主导地位。

主要最终用户包括医院和诊所、诊断实验室和其他实体。在医疗保健基础设施投资增加以及与研究机构合作的推动下，诊断实验室预计从 2024 年到 2032 年将以 14.5% 的复合年增长率成长。这些进步正在提高测试能力并促进创新。

由于血液癌症发病率上升以及先进检测技术的迅速采用，北美在 2023 年占据全球市场最大份额，达到 45.6%。在医疗基础设施的进步、有利的报销政策以及监管机构对新型检测方法的认可的支持下，美国市场从 2024 年到 2032 年的复合年增长率预计将达到 14.1%。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 提高血液癌症的诊断率
    • 改善医疗基础设施
    • 诊断技术的进步
    • 血液系统恶性肿瘤的发生率增加
  • 产业陷阱与挑战
    • 来自替代诊断方法的竞争
    • 维护和营运成本高
• 成长潜力分析
• 监管环境
• 未来市场趋势
• 波特的分析
• PESTEL分析

第 4 章：竞争格局

• 介绍
• 公司市占率分析
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 战略仪表板

第 5 章：市场估计与预测：按产品和服务划分，2021 - 2032 年

• 主要趋势
• 乐器
  • 新一代定序 (NGS)
  • 聚合酶炼式反应 (PCR)
  • 流式细胞仪
  • 细胞遗传学
  • 免疫组织化学 (IHC)
  • 其他技术
• 试剂盒和试剂
• 软体与服务

第 6 章：市场估计与预测：按癌症类型，2021 - 2032 年

• 主要趋势
• 白血病
  • 急性淋巴性白血病（ALL）
  • 急性骨髓性白血病（AML）
  • 慢性淋巴性白血病（CLL）
  • 慢性骨髓性白血病（CML）
• 淋巴瘤
  • 霍奇金淋巴瘤
  • 非何杰金氏淋巴瘤 (NHL)
• 其他癌症类型

第 7 章：市场估计与预测：按最终用途，2021 - 2032 年

• 主要趋势
• 医院和诊所
• 诊断实验室
• 其他最终用户

第 8 章：市场估计与预测：按地区，2021 - 2032

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
  • 欧洲其他地区
• 亚太地区
  • 日本
  • 中国
  • 印度
  • 澳洲
  • 韩国
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 拉丁美洲其他地区
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋
  • 中东和非洲其他地区

第 9 章：公司简介

• Abbott Laboratories
• ARUP Laboratories
• Bio-Rad Laboratories Inc.
• Danaher Corporation (Integrated DNA Technologies, Inc.)
• Entrogen Inc.
• F. Hoffmann-La Roche Ltd
• Illumina, Inc.
• Invivoscribe, Inc.
• Invitae Corporation (Archerdx, Inc.)
• QIAGEN N.V.
• Thermo Fisher Scientific, Inc.
• Vela Diagnostics

The Global Hemato Oncology Testing Market was valued at USD 3.2 billion in 2023 and is projected to grow at a CAGR of 14.2% from 2024 to 2032. This growth is driven by the increasing prevalence of hematological cancers, including leukemia, lymphoma, and multiple myeloma, leading to a rise in demand for advanced diagnostic tests. The advancements in diagnostic technology, in line with greater awareness of hematologic cancers and the benefits of early detection, are significantly boosting the market. The growing focus on early screening and the development of more specialized testing solutions continue to propel the market forward.

Hemato oncology testing is dedicated to the detection, diagnosis, and monitoring of blood-related cancers. These tests identify genetic mutations, chromosomal abnormalities, and other biomarkers associated with hematologic malignancies, enhancing the ability to manage these diseases more effectively.

The overall hemato oncology testing industry is categorized based on Product and Service, Cancer Type, Technology, End-use, and Region.

The market is segmented into kits and reagents, instruments, and software and services. The instrument segment includes next-generation sequencing (NGS), polymerase chain reaction (PCR), flow cytometry, cytogenetics, and immunohistochemistry. In 2023, the kits and reagents segment dominated with a revenue of USD 1.7 billion, driven by the increasing demand for personalized medicine and advancements in diagnostic testing. Continuous research and development in hematology diagnostics further stimulates market expansion, with regulatory approvals from bodies like the FDA and EMA supporting growth.

The market is categorized into leukemia, lymphoma, and other cancers. Lymphoma held a leading market share of 51.3% in 2023 due to the rising incidence of both Hodgkin's and non-Hodgkin's lymphoma. Improved screening programs and diagnostic techniques contribute to the segment's dominance.

Key end-users include hospitals and clinics, diagnostic laboratories, and other entities. Diagnostic laboratories are expected to grow at a CAGR of 14.5% from 2024 to 2032, driven by increased investments in healthcare infrastructure and collaboration with research institutions. These advancements are improving testing capabilities and fostering innovation.

North America held the largest share of the global market in 2023, with 45.6%, due to rising rates of hematological cancers and the swift adoption of advanced testing technologies. The U.S. market is set to grow at a CAGR of 14.1% from 2024 to 2032, supported by advancements in healthcare infrastructure, favorable reimbursement policies, and regulatory endorsements for novel testing methods.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360º synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increase in diagnosis rate of hematological cancers
    • 3.2.1.2 Improved healthcare infrastructure
    • 3.2.1.3 Advancement in diagnostic technologies
    • 3.2.1.4 Increasing incidence of hematologic malignancies
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Competition from alternative diagnostic methods
    • 3.2.2.2 High maintenance and operational cost
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Future market trends
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Product and Service, 2021 - 2032 ($ Million)

• 5.1 Key trends
• 5.2 Instrument
  • 5.2.1 Next-generation sequencing (NGS)
  • 5.2.2 Polymerase chain reaction (PCR)
  • 5.2.3 Flow cytometry
  • 5.2.4 Cytogenetics
  • 5.2.5 Immunohistochemistry (IHC)
  • 5.2.6 Other technologies
• 5.3 Kits and reagents
• 5.4 Software and service

Chapter 6 Market Estimates and Forecast, By Cancer Type, 2021 - 2032 ($ Million)

• 6.1 Key trends
• 6.2 Leukemia
  • 6.2.1 Acute lymphoblastic leukemia (ALL)
  • 6.2.2 Acute myeloid leukemia (AML)
  • 6.2.3 Chronic lymphocytic leukemia (CLL)
  • 6.2.4 Chronic myeloid leukemia (CML)
• 6.3 Lymphoma
  • 6.3.1 Hodgkin lymphoma
  • 6.3.2 Non-Hodgkin lymphoma (NHL)
• 6.4 Other cancer types

Chapter 7 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Million)

• 7.1 Key trends
• 7.2 Hospitals and clinics
• 7.3 Diagnostic laboratories
• 7.4 Other end-users

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Million)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
  • 8.3.7 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 Japan
  • 8.4.2 China
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 Abbott Laboratories
• 9.2 ARUP Laboratories
• 9.3 Bio-Rad Laboratories Inc.
• 9.4 Danaher Corporation (Integrated DNA Technologies, Inc.)
• 9.5 Entrogen Inc.
• 9.6 F. Hoffmann-La Roche Ltd
• 9.7 Illumina, Inc.
• 9.8 Invivoscribe, Inc.
• 9.9 Invitae Corporation (Archerdx, Inc.)
• 9.10 QIAGEN N.V.
• 9.11 Thermo Fisher Scientific, Inc.
• 9.12 Vela Diagnostics